Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer
Clinical and translational medicine, 2020.
Clinicaltrials.gov, NCT02824458, date of registration June 23, 2016.
Full Text (Upload PDF)
PPT (Upload PPT)